Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.